Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine
Status:
Completed
Trial end date:
2020-11-17
Target enrollment:
Participant gender:
Summary
Phase 1, single -center study in 2 parts. The study designs for each part are well
established for first-in-human studies and are appropriate to assess safety, tolerability and
preliminary pharmacokinetics& pharmacodynamics.
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborators:
Nucleus Network Nucleus Network Ltd Southern Star Research Pty Ltd.
Treatments:
Artemether Artemether, Lumefantrine Drug Combination Lumefantrine